Virtual mutation and directional evolution of anti-amoxicillin ScFv antibody for immunoassay of penicillins in milk

2017 ◽  
Vol 517 ◽  
pp. 9-17 ◽  
Author(s):  
Xin He ◽  
Chang Fei Duan ◽  
Yong Hua Qi ◽  
Jun Dong ◽  
Geng Nan Wang ◽  
...  
2021 ◽  
Author(s):  
Fangyu Wang ◽  
Ning Li ◽  
Yunshang Zhang ◽  
Xuxefeng Sun ◽  
Yali Zhao ◽  
...  

Abstract A recombinant anti-enrofloxacin single-chain antibody (scFv) was produced for the detection of enrofloxacin. An immunized mouse phage display scFv library with a capacity of 2.35×109 CFU/mL was constructed and used for anti-enrofloxacin scFv screening. After four rounds of bio-panning, 10 positives were isolated and identified successfully. The highest positive scFv was expressed in E. coli BL21. Then, its recognition mechanisms were studied using the molecular docking method. The result showed the amino acid residues Leu121 were the key residues for the binding of ScFv to ENR. Based on the results of virtual mutation, the ScFv antibody was evolved by directional mutagenesis of contact amino acid residue Leu121 to Asn. After the expression and purification, an indirect competitive enzyme-linked immunosorbent assay (IC-ELISA) based on the parental and mutant ScFv were established for enrofloxacin respectively. The IC50 value of the assay established with the ScFv mutant was 1.63 ng/mL, while the parental ScFv was 21.08 ng/mL, this result showed highly increased affinity with up to 12.9-folds improved sensitivity. The mean recovery for ENR ranged from 71.80% to 117.35% with 10.46% relative standard deviation between the intra-assay and the inter-assay. The results indicate that we have obtained a highly sensitive anti-ENR scFv by the phage library construction and directional evolution, and the scFv-based IC-ELISA is suitable for the detection of ENR residue in animal derived edible tissues and milk.


2017 ◽  
Vol 9 (30) ◽  
pp. 4455-4463 ◽  
Author(s):  
Fang Shu Shi ◽  
Lei Zhang ◽  
Wan Qiu Xia ◽  
Jing Liu ◽  
Hui Cai Zhang ◽  
...  

Production and directional evolution of a ScFv antibody based on computational simulation for immunoassay of phenothiazines in meat.


2016 ◽  
Vol 64 (42) ◽  
pp. 7957-7965 ◽  
Author(s):  
Jian Ping Wang ◽  
Jun Dong ◽  
Chang Fei Duan ◽  
Hui Cai Zhang ◽  
Xin He ◽  
...  

2021 ◽  
Author(s):  
Guangxu Xing ◽  
Yunshang Zhang ◽  
Fangyu Wang ◽  
Liuding Wen ◽  
Gaiping Zhang

Abstract A recombinant anti-enrofloxacin single-chain antibody (scFv) was produced for the detection of enrofloxacin. An immunized mouse phage display scFv library with a capacity of 2.35×109 CFU/mL was constructed and used for anti-enrofloxacin scFv screening. After four rounds of bio-panning, 10 positives were isolated and identified successfully. The highest positive scFv was expressed in E. coli BL21. Then, its recognition mechanisms were studied using the molecular docking method. The result showed the amino acid residues Leu121 were the key residues for the binding of ScFv to ENR. Based on the results of virtual mutation, the ScFv antibody was evolved by directional mutagenesis of contact amino acid residue Leu121 to Asn. After the expression and purification, an indirect competitive enzyme-linked immunosorbent assay (IC-ELISA) based on the parental and mutant ScFv were established for enrofloxacin respectively. The IC50 value of the assay established with the ScFv mutant was 1.63 ng/mL, while the parental ScFv was 21.08 ng/mL, this result showed highly increased affinity with up to 12.9-folds improved sensitivity. The mean recovery for ENR ranged from 71.80% to 117.35% with 10.46% relative standard deviation between the intra-assay and the inter-assay. The results indicate that we have obtained a highly sensitive anti-ENR scFv by the phage library construction and directional evolution, and the scFv-based IC-ELISA is suitable for the detection of ENR residue in animal derived edible tissues and milk.


2013 ◽  
Vol 14 (6) ◽  
pp. 571-581 ◽  
Author(s):  
Tianhe Li ◽  
Liming Xu ◽  
Guiping Ren ◽  
Chengkai Yin ◽  
Bing Zhou ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zahra Shadman ◽  
Safar Farajnia ◽  
Mohammad Pazhang ◽  
Mohammadreza Tohidkia ◽  
Leila Rahbarnia ◽  
...  

Abstract Background Pseudomonas aeruginosa is the leading cause of nosocomial infections, especially in people with a compromised immune system. Targeting virulence factors by neutralizing antibodies is a novel paradigm for the treatment of antibiotic-resistant pseudomonas infections. In this respect, exotoxin A is one of the most potent virulence factors in P. aeruginosa. The present study was carried out to identify a novel human scFv antibody against the P. aeruginosa exotoxin A domain I (ExoA-DI) from a human scFv phage library. Methods The recombinant ExoA-DI of P. aeruginosa was expressed in E. coli, purified by Ni-NTA column, and used for screening of human antibody phage library. A novel screening procedure was conducted to prevent the elimination of rare specific clones. The phage clone with high reactivity was evaluated by ELISA and western blot. Results Based on the results of polyclonal phage ELISA, the fifth round of biopanning leads to the isolation of several ExoA-DI reactive clones. One positive clone with high affinity was selected by monoclonal phage ELISA and used for antibody expression. The purified scFv showed high reactivity with the recombinant domain I and full-length native exotoxin A. Conclusions The purified anti-exotoxin A scFv displayed high specificity against exotoxin A. The human scFv identified in this study could be the groundwork for developing a novel therapeutic agent to control P. aeruginosa infections.


2015 ◽  
Vol 5 (Suppl 1) ◽  
pp. 621-627 ◽  
Author(s):  
Kamal Veisi ◽  
Safar Farajnia ◽  
Nosratollah Zarghami ◽  
Hamid Reza Khoram Khorshid ◽  
Nasser Samadi ◽  
...  

2013 ◽  
Vol 397 (1-2) ◽  
pp. 61-65 ◽  
Author(s):  
Sarah L. Appleby ◽  
Yazad Irani ◽  
Lauren A. Mortimer ◽  
Helen M. Brereton ◽  
Sonja Klebe ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document